What does EPICS THERAPEUTICS do?

EPICS THERAPEUTICS is a research organisation in Charleroi. Public Limited, started on 20 February 2018, 1 establishment.

What is the address of EPICS THERAPEUTICS?

The registered office of EPICS THERAPEUTICS is located at Rue Adrienne Bolland 47, 6041 Charleroi.

Is EPICS THERAPEUTICS still active?

Yes. According to the CBE (29 October 2026) EPICS THERAPEUTICS is active, legal situation “Normale toestand”, started on 20 February 2018.

Is EPICS THERAPEUTICS registered on Peppol?

Yes, EPICS THERAPEUTICS is registered on the Peppol network with ID 0208:0690759071.

What is the enterprise number of EPICS THERAPEUTICS?

The enterprise number of EPICS THERAPEUTICS is BE0690759071.

When was EPICS THERAPEUTICS founded?

EPICS THERAPEUTICS was founded on 20 February 2018.

Who are the directors of EPICS THERAPEUTICS?

According to the 2025 annual accounts, the directors of EPICS THERAPEUTICS are: GEMA SRL, Newton Biocapital Partners SRL, JCO Consulting SRL, JUNOMATI BV, Sparaxis SA, EJM Consulting, SFPI SA, Graeme Fraser.

Is EPICS THERAPEUTICS a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 20 February 2018; 5 annual accounts filed, latest fiscal year 2025; 8 directors known from the annual account.

How much profit did EPICS THERAPEUTICS make in 2025?

EPICS THERAPEUTICS recorded a loss after taxes of € 5,794,119 in financial year 2025.

What is the revenue of EPICS THERAPEUTICS?

As a small company, EPICS THERAPEUTICS is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 4,234,308.

How much does an employee at EPICS THERAPEUTICS earn?

The average wage cost per full-time employee at EPICS THERAPEUTICS was € 99,500 in 2025: staff costs of € 3.2 million for 32.2 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does EPICS THERAPEUTICS have?

According to the 2025 annual accounts, EPICS THERAPEUTICS has 32.2 full-time equivalents (FTE).

Does EPICS THERAPEUTICS have a website?

Yes, EPICS THERAPEUTICS has a website at epicstherapeutics.com.

EPICS THERAPEUTICS (Public Limited) - Charleroi

Dossier EPICS THERAPEUTICS, printed on 29 October 2026 from databakkes.be/en/0690759071/epics-therapeutics. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.
Figures corrected NBB

Corrected annual account filed for 2024.

Financials

Financial year 2025

EPICS THERAPEUTICS from Charleroi, company number BE0690759071, closed financial year 2025 with a result of € -5.8 million after tax. For that financial year EPICS THERAPEUTICS recorded a gross margin of € 4.2 million and equity of € 9.1 million. Compared with financial year 2024, the result moved from € -4.8 million to € -5.8 million. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 23, 2026.

What it is worth Growing

€ 9.1 million

▲ 15% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -5.8 million

▼ 20 % more loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 9.2 million

▲ 5% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -10.6 million.

People and assets in 2025

Full-time equivalents

32.2

▲ 0.5 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 3.2 million

▲ 3% vs 2024

€ 99,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 171,454

▲ 208% vs 2024

Of which on lease € 74,608.

Debts at end 2025

Bank debt ≈ 14 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 3.8 million

▼ 6% vs 2024

€ 268,770 is repaid this year. At this pace the long-term loan is gone in ≈ 14 years.

Owed to suppliers

€ 1.3 million

▲ 109% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 532,415

▲ 10% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	-	-	€ 4,827,700 Revenue 2024: € 4,827,700 First fiscal year in the series	-
Gross margin	€ 4,588,933 Gross margin 2022: € 4,588,933 First fiscal year in the series	€ 3,355,981 Gross margin 2023: € 3,355,981 ▼ 27% vs 2022 (€ 4,588,933) Unfavourable step	€ 4,038,507 Gross margin 2024: € 4,038,507 ▲ 20% vs 2023 (€ 3,355,981) Favourable step	€ 4,234,308 Gross margin 2025: € 4,234,308 ▲ 5% vs 2024 (€ 4,038,507) Favourable step	▲ 5%
Profit after taxes	€ -5,399,664 Profit after taxes 2022: € -5,399,664 First fiscal year in the series	€ -6,256,176 Profit after taxes 2023: € -6,256,176 ▼ € 856,512 vs 2022 (€ -5,399,664) Unfavourable step	€ -4,840,047 Profit after taxes 2024: € -4,840,047 ▲ € 1.4 million vs 2023 (€ -6,256,176) Favourable step	€ -5,794,119 Profit after taxes 2025: € -5,794,119 ▼ € 954,072 vs 2024 (€ -4,840,047) Unfavourable step	▼ € 954,072
Equity	€ 14,002,616 Equity 2022: € 14,002,616 First fiscal year in the series	€ 7,746,440 Equity 2023: € 7,746,440 ▼ 45% vs 2022 (€ 14,002,616) Unfavourable step	€ 7,906,432 Equity 2024: € 7,906,432 ▲ 2% vs 2023 (€ 7,746,440) Favourable step	€ 9,112,305 Equity 2025: € 9,112,305 ▲ 15% vs 2024 (€ 7,906,432) Favourable step	▲ 15%
Total debts	€ 2,009,756 Total debts 2022: € 2,009,756 First fiscal year in the series	€ 1,570,760 Total debts 2023: € 1,570,760 ▼ 22% vs 2022 (€ 2,009,756) Favourable step	€ 5,915,343 Total debts 2024: € 5,915,343 ▲ 277% vs 2023 (€ 1,570,760) Unfavourable step	€ 5,593,028 Total debts 2025: € 5,593,028 ▼ 5% vs 2024 (€ 5,915,343) Favourable step	▼ 5%
Cash	€ 12,177,071 Cash 2022: € 12,177,071 First fiscal year in the series	€ 4,161,021 Cash 2023: € 4,161,021 ▼ 66% vs 2022 (€ 12,177,071) Unfavourable step	€ 8,780,680 Cash 2024: € 8,780,680 ▲ 111% vs 2023 (€ 4,161,021) Favourable step	€ 9,195,844 Cash 2025: € 9,195,844 ▲ 5% vs 2024 (€ 8,780,680) Favourable step	▲ 5%
Land & buildings	€ 744,868 Land & buildings 2022: € 744,868 First fiscal year in the series	€ 854,305 Land & buildings 2023: € 854,305 ▲ 15% vs 2022 (€ 744,868) Unchanged	€ 787,775 Land & buildings 2024: € 787,775 ▼ 8% vs 2023 (€ 854,305) Unchanged	€ 732,056 Land & buildings 2025: € 732,056 ▼ 7% vs 2024 (€ 787,775) Unchanged	▼ 7%
Retained profit	€ -16,430,569 Retained profit 2022: € -16,430,569 First fiscal year in the series	€ -22,686,745 Retained profit 2023: € -22,686,745 ▼ € 6.3 million vs 2022 (€ -16,430,569) Unfavourable step	€ -4,840,047 Retained profit 2024: € -4,840,047 ▲ € 17.8 million vs 2023 (€ -22,686,745) Favourable step	€ -10,634,166 Retained profit 2025: € -10,634,166 ▼ € 5.8 million vs 2024 (€ -4,840,047) Unfavourable step	▼ € 5.8 million
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 159,064 Bank debt 2023: € 159,064 Unchanged (€ 0) Unfavourable step	€ 4,026,455 Bank debt 2024: € 4,026,455 ▲ € 3.9 million vs 2023 (€ 159,064) Unfavourable step	€ 3,790,547 Bank debt 2025: € 3,790,547 ▼ 6% vs 2024 (€ 4,026,455) Favourable step	▼ 6%
Balance sheet total	€ 16,012,372 Balance sheet total 2022: € 16,012,372 First fiscal year in the series	€ 9,317,200 Balance sheet total 2023: € 9,317,200 ▼ 42% vs 2022 (€ 16,012,372) Unchanged	€ 13,821,775 Balance sheet total 2024: € 13,821,775 ▲ 48% vs 2023 (€ 9,317,200) Unchanged	€ 14,705,334 Balance sheet total 2025: € 14,705,334 ▲ 6% vs 2024 (€ 13,821,775) Unchanged	▲ 6%
Employees (FTE)	32 Employees (FTE) 2022: 32 First fiscal year in the series	32.4 Employees (FTE) 2023: 32.4 ▲ 0.4 vs 2022 (32) Unchanged	31.7 Employees (FTE) 2024: 31.7 ▼ 0.7 vs 2023 (32.4) Unchanged	32.2 Employees (FTE) 2025: 32.2 ▲ 0.5 vs 2024 (31.7) Unchanged	▲ 0.5

Key figures of EPICS THERAPEUTICS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to EPICS THERAPEUTICS?

What happened at EPICS THERAPEUTICS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2030 Newton Biocapital Partners SRL stepped down as director. NBB
2030 JCO Consulting SRL stepped down as director. NBB
2030 JUNOMATI BV stepped down as director. NBB
2030 Sparaxis SA stepped down as director. NBB
2030 EJM Consulting stepped down as director. NBB
2030 SFPI SA stepped down as director. NBB
2030 Graeme Fraser stepped down as director. NBB
Jun 23, 2026 New annual accounts for financial year 2025: loss of € 5.8 million. Source: NBB ↗

In short

From € 5.4 million loss in 2022 to € 5.8 million loss in 2025.

On average € 131,500 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Newton Biocapital I, pricaf privée de droit belge 24.4%

Wallonie Entreprendre 14.3%

FEDERALE PARTICIPATIE- EN INVESTERINGSMAATSCHAPPIJ 12.8%

BIO CAP INVEST 9.3%

The stake of Newton Biocapital I, pricaf privée de droit belge, Wallonie Entreprendre, FEDERALE PARTICIPATIE- EN INVESTERINGSMAATSCHAPPIJ, BIO CAP INVEST, Fund+, INVESTSUD TECH comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

EPICS THERAPEUTICS

The shares are held by Newton Biocapital I, pricaf privée de droit belge (24.4%), Wallonie Entreprendre (14.3%), FEDERALE PARTICIPATIE- EN INVESTERINGSMAATSCHAPPIJ (12.8%), BIO CAP INVEST (9.3%), Fund+ (6.3%) and INVESTSUD TECH (4.5%).